BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 214.8 EUR | +4.27% |
|
+4.78% | -8.52% |
| 05-15 | Sector Update: Health Care Stocks Advance Late Wednesday Afternoon | MT |
| 05-15 | Sector Update: Health Care Stocks Advance in Afternoon Trading | MT |
| Sales 2024 * | 9.52B 8.75B 750B | Sales 2025 * | 9.55B 8.77B 752B | Capitalization | 34.26B 31.47B 2,700B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.9B 1.74B 149B | Net income 2025 * | 2.21B 2.03B 174B | EV / Sales 2024 * | 3.92 x |
| Net Debt 2024 * | 3.01B 2.77B 238B | Net Debt 2025 * | 536M 492M 42.23B | EV / Sales 2025 * | 3.64 x |
| P/E ratio 2024 * |
18.1
x | P/E ratio 2025 * |
15.7
x | Employees | 7,570 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.81% |
More Fundamentals
* Assessed data
More news
Latest transcript on Biogen Inc.
More recommendations
More press releases
More news
| 1 day | +4.27% | ||
| 1 week | +4.78% | ||
| Current month | +5.71% | ||
| 1 month | +14.65% | ||
| 3 months | +3.67% | ||
| 6 months | +1.70% | ||
| Current year | -8.52% |
1 week
203.30
214.80
1 month
177.65214.80
Current year
177.65245.60
1 year
177.65309.80
3 years
174.26351.70
5 years
174.26351.70
10 years
174.26447.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 13/11/22 | |
| Director of Finance/CFO | 60 | 14/08/20 | |
Nicole Murphy
COO | Chief Operating Officer | - | 31/12/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 31/12/09 |
William Hawkins
BRD | Director/Board Member | 70 | 18/06/19 |
Caroline Dorsa
CHM | Chairman | 64 | 02/01/10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/05/24 | 214.8 | +4.27% | 2,646 |
| 14/05/24 | 206 | -0.68% | 203 |
| 13/05/24 | 207.4 | +0.44% | 125 |
| 10/05/24 | 206.5 | +1.23% | 262 |
| 09/05/24 | 204 | -0.49% | 308 |
Delayed Quote Xetra, May 15, 2024 at 04:35 pm
More quotes
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
20/06/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
235.3
USD
Average target price
285.9
USD
Spread / Average Target
+21.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.07% | 91.42B | |
| +2.76% | 41.08B | |
| +55.32% | 25.27B | |
| -16.61% | 15.27B | |
| -9.14% | 12.81B | |
| -12.11% | 11.6B | |
| -43.61% | 11.42B | |
| +7.79% | 9.16B | |
| -7.49% | 8.22B |
- Stock Market
- Equities
- BIIB Stock
- IDP Stock
